Combination of Ceftazidime-Avibactam and Meropenem for the Treatment of Pneumonia and Bloodstream Infections Caused by Pan-Drug Resistant Pseudomonas aeruginosa ST244: A Case Report
Abstract
Case presentation: We describe a challenging case of a woman with Pseudomonas aeruginosa pneumonia and bloodstream infections following cardiothoracic surgery. This strain exhibited a pan-drug resistance phenotype belonging to the high-risk clone ST244. Finally, she was successfully treated by antibiotic therapy with ceftazidime/avibactam (CAZ/AVI) and meropenem (MEPM).
Conclusion: This case suggests that the combination of CAZ/AVI and MEPM may represent a potential therapeutic option for severe infections caused by pan-drug-resistant Pseudomonas aeruginosa (PDR-PA).
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.